Cargando…

Geographical Variance in the Use of Tranexamic Acid for Major Trauma Patients

Background and Objectives: The CRASH-2 trial is the largest randomised control trial examining tranexamic acid (TXA) for injured patients. Since its publication, debate has arisen around whether results could be applied to mature trauma systems in developed nations, with global opinion divided. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Walsh, Kieran, O’Keeffe, Francis, Mitra, Biswadev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780548/
https://www.ncbi.nlm.nih.gov/pubmed/31480783
http://dx.doi.org/10.3390/medicina55090561
_version_ 1783457161986179072
author Walsh, Kieran
O’Keeffe, Francis
Mitra, Biswadev
author_facet Walsh, Kieran
O’Keeffe, Francis
Mitra, Biswadev
author_sort Walsh, Kieran
collection PubMed
description Background and Objectives: The CRASH-2 trial is the largest randomised control trial examining tranexamic acid (TXA) for injured patients. Since its publication, debate has arisen around whether results could be applied to mature trauma systems in developed nations, with global opinion divided. The aim of this study was to determine if, among trauma patients in or at significant risk of major haemorrhages, there is an association of geographic region with the proportion of patients that received tranexamic acid. Materials and Methods: We conducted a systematic review of the literature. Potentially eligible papers were first screened via title and abstract screening. A full copy of the remaining papers was then obtained and screened for final inclusion. The Newcastle–Ottawa Scale for non-randomised control trials was used for quality assessment of the final studies included. A meta-analysis was conducted using a random-effects model, reporting variation in use sub-grouped by geographical location. Results: There were 727 papers identified through database searching and 23 manuscripts met the criteria for final inclusion in this review. There was a statistically significant variation in the use of TXA for included patients. Europe and Oceania had higher usage rates of TXA compared to other continents. Use of TXA in Asia and Africa was significantly less than other continents and varied use was observed in North America. Conclusions: A large geographical variance in the use of TXA for trauma patients in or at significant risk of major haemorrhage currently exists. The populations in Asia and Africa, where the results of CRASH-2 could be most readily generalised to, reported low rates of use. The reason why remains unclear and further research is required to standardise the use of TXA for trauma resuscitation.
format Online
Article
Text
id pubmed-6780548
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67805482019-10-30 Geographical Variance in the Use of Tranexamic Acid for Major Trauma Patients Walsh, Kieran O’Keeffe, Francis Mitra, Biswadev Medicina (Kaunas) Review Background and Objectives: The CRASH-2 trial is the largest randomised control trial examining tranexamic acid (TXA) for injured patients. Since its publication, debate has arisen around whether results could be applied to mature trauma systems in developed nations, with global opinion divided. The aim of this study was to determine if, among trauma patients in or at significant risk of major haemorrhages, there is an association of geographic region with the proportion of patients that received tranexamic acid. Materials and Methods: We conducted a systematic review of the literature. Potentially eligible papers were first screened via title and abstract screening. A full copy of the remaining papers was then obtained and screened for final inclusion. The Newcastle–Ottawa Scale for non-randomised control trials was used for quality assessment of the final studies included. A meta-analysis was conducted using a random-effects model, reporting variation in use sub-grouped by geographical location. Results: There were 727 papers identified through database searching and 23 manuscripts met the criteria for final inclusion in this review. There was a statistically significant variation in the use of TXA for included patients. Europe and Oceania had higher usage rates of TXA compared to other continents. Use of TXA in Asia and Africa was significantly less than other continents and varied use was observed in North America. Conclusions: A large geographical variance in the use of TXA for trauma patients in or at significant risk of major haemorrhage currently exists. The populations in Asia and Africa, where the results of CRASH-2 could be most readily generalised to, reported low rates of use. The reason why remains unclear and further research is required to standardise the use of TXA for trauma resuscitation. MDPI 2019-09-02 /pmc/articles/PMC6780548/ /pubmed/31480783 http://dx.doi.org/10.3390/medicina55090561 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Walsh, Kieran
O’Keeffe, Francis
Mitra, Biswadev
Geographical Variance in the Use of Tranexamic Acid for Major Trauma Patients
title Geographical Variance in the Use of Tranexamic Acid for Major Trauma Patients
title_full Geographical Variance in the Use of Tranexamic Acid for Major Trauma Patients
title_fullStr Geographical Variance in the Use of Tranexamic Acid for Major Trauma Patients
title_full_unstemmed Geographical Variance in the Use of Tranexamic Acid for Major Trauma Patients
title_short Geographical Variance in the Use of Tranexamic Acid for Major Trauma Patients
title_sort geographical variance in the use of tranexamic acid for major trauma patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780548/
https://www.ncbi.nlm.nih.gov/pubmed/31480783
http://dx.doi.org/10.3390/medicina55090561
work_keys_str_mv AT walshkieran geographicalvarianceintheuseoftranexamicacidformajortraumapatients
AT okeeffefrancis geographicalvarianceintheuseoftranexamicacidformajortraumapatients
AT mitrabiswadev geographicalvarianceintheuseoftranexamicacidformajortraumapatients